CCR2 inhibition: a panacea for diabetic kidney disease?

Affiliations

¹ Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: mweir@medicine.umaryland.edu.

Comment

Matthew R Weir. Lancet Diabetes Endocrinol. 2015 Sep.

. 2015 Sep;3(9):666-7.

doi: 10.1016/S2213-8587(15)00286-7. Epub 2015 Aug 9.

¹ Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD 21201, USA. Electronic address: mweir@medicine.umaryland.edu.

No abstract available

Comment on

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial.
de Zeeuw D, Bekker P, Henkel E, Hasslacher C, Gouni-Berthold I, Mehling H, Potarca A, Tesar V, Heerspink HJ, Schall TJ; CCX140-B Diabetic Nephropathy Study Group. de Zeeuw D, et al. Lancet Diabetes Endocrinol. 2015 Sep;3(9):687-96. doi: 10.1016/S2213-8587(15)00261-2. Epub 2015 Aug 9. Lancet Diabetes Endocrinol. 2015. PMID: 26268910 Clinical Trial.